©The Author(s) 2016.
World J Gastroenterol. Mar 28, 2016; 22(12): 3404-3411
Published online Mar 28, 2016. doi: 10.3748/wjg.v22.i12.3404
Published online Mar 28, 2016. doi: 10.3748/wjg.v22.i12.3404
Table 4 Features of hepatocellular carcinoma patients based on the antiviral therapy status
| Variables | HCC group on anti-viral therapy (n = 9) | HCC group on no therapy (n = 4) |
| Mean age ± SD, yr | 53.2 ± 8.5 | 46.5 ± 20.5 |
| Male: female | 7:2 | 2:2 |
| HBeAg negative | 8/9 | 4/4 |
| Undetectable HBV DNA | 8/9 | 0/4 |
| Cirrhosis | 4/9 | 0/4 |
| Invasive HCC | 3/9 | 4/4 |
| Tumor: | ||
| Well differentiation | 6/9 | 1/4 |
| Moderate differentiation | 3/9 | 3/4 |
| Intrahepatic HBcAg staining | ||
| (+) Only in tumor tissues | 4/9 | 1/4 |
| (+) Only in non-tumor tissues | 3/9 | 1/4 |
| (+) Both in tumor and non-tumor tissues | 2/9 | 2/4 |
| Intrahepatic HBsAg staining | ||
| (+) Only in tumor tissues | 1/9 | 0/4 |
| (+) Only in non-tumor tissues | 3/9 | 2/4 |
| (+) Both in tumor and non-tumor tissues | 3/9 | 1/4 |
- Citation: Safaie P, Poongkunran M, Kuang PP, Javaid A, Jacobs C, Pohlmann R, Nasser I, Lau DT. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma. World J Gastroenterol 2016; 22(12): 3404-3411
- URL: https://www.wjgnet.com/1007-9327/full/v22/i12/3404.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i12.3404